DALLAS, TX -- November 2, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) today announced the acquisition of Telluride Health Company, the innovator behind Telluride Happy Water, a refreshing and delicious drink that enhances the cannabis experience as a beverage before partaking or during when used in a water-pipe.
The acquisition is made in conjunction with the North American Cannabis Holdings, (USOTC: USMJ) (“USMJ”) spin-off of its AmeriCanna Cafe business announced yesterday. USMJ affected the spin-off by selling the AmeriCanna Cafe business to Priority Aviation (USOTC: PJET) (“PJET”). The USMJ transaction with PJET includes a planned dividend distribution of PJET shares to USMJ shareholders. As the PJET public holding company changes names and business directions to establish itself as a cannabis themed restaurant group, its operating subsidiary Telluride Health Company, has been sold to PURA adding a third cannabis sector beverage brand, Telluride Happy Water, to PURA’s current EVERx CBD Sports Water and THCSavor brands.
Telluride Happy Water has a higher level of dissolved oxygen in it than almost any bottled water on the market. A patented technology and formula reduces the size of water molecules which creates a platform that accelerates the uptake of anything mixed with or filtered through the patented water technology. This is how our product exponentially increases a cannabis high.
The cannabis-infused edibles market is projected to make up a $2.3-billion market in 2018 and to become a $5.3-billion market within the next five years, according to data from cannabis market research firm Brightfield Group.
With the Telluride Health Company acquisition already in the works for some time now, PURA expects Telluride Happy Water to hit shelves before Christmas. PURA has already initiated its first production run of Telluride Happy Water with co-packer and partner Alkame Holdings, Inc. (USOTC: ALKM).
Puration plans to publish an online presentation detailing the Telluride Happy Water acquisition and business plan on Monday, November 5, 2018. The presentation was originally scheduled for today and intended for release prior to the Telluride Health Company acquisition closing. In light of the earlier than anticipated closing, the presentation is being update and rescheduled for one business day later.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.